| Literature DB >> 27482518 |
So Young Lim1, Eun Jin Kim1, Arang Kim1, Hee Jae Lee2, Hyun Jin Choi2, Soo Jin Yang2.
Abstract
Dietary intake and nutritional status of individuals are important factors affecting mental health and the development of psychiatric disorders. Majority of scientific evidence relating to mental health focuses on depression, cognitive function, and dementia, and limited evidence is available about other psychiatric disorders including schizophrenia. As life span of human being is increasing, the more the prevalence of mental disorders is, the more attention rises. Lists of suggested nutritional components that may be beneficial for mental health are omega-3 fatty acids, phospholipids, cholesterol, niacin, folate, vitamin B6, and vitamin B12. Saturated fat and simple sugar are considered detrimental to cognitive function. Evidence on the effect of cholesterol is conflicting; however, in general, blood cholesterol levels are negatively associated with the risk of depression. Collectively, the aims of this review are to introduce known nutritional factors for mental health, and to discuss recent issues of the nutritional impact on cognitive function and healthy brain aging.Entities:
Keywords: Cognitive function; Dementia; Depression; Healthy brain aging; Mental health
Year: 2016 PMID: 27482518 PMCID: PMC4967717 DOI: 10.7762/cnr.2016.5.3.143
Source DB: PubMed Journal: Clin Nutr Res ISSN: 2287-3732
Double blind, randomized, placebo-controlled trials involving omega-3 fatty acids (FAs) supplementation and major mental disorders
| Ref. No. | Study design | Daily amounts of omega-3 FAs | Main findings |
|---|---|---|---|
| [ | 33 mild AD patients, omega-3 FAs (n = 18) and placebo (n = 15) for 6 mon | 2.3 g (0.6 g EPA + 1.7 g DHA) | Reduce CSF levels of AD biomarkers |
| [ | 295 mild to moderate AD patients, DHA (n = 171) and placebo (n = 124) for 18 mon | 2 g DHA | No effect on cognitive function |
| [ | 46 depressed women aged 66–95 years, omega-3 FAs (n = 22) and placebo (n = 24) for 8 wk | 2.5 g (1.67 g EPA + 0.83 g DHA) | Ameliorate depressive symptoms and improve quality of life |
| [ | 36 pregnant/depressive women, omega-3 FAs (n = 18) and placebo (n = 18) for 8 wk | 3.4 g (2.2 g EPA + 1.2 g DHA) | Lower depressive symptom ratings on the EPDS and BDI |
| [ | 60 schizophrenia patients, omega-3 FAs (n = 30) and placebo (n = 30) for 8 wk | 1.0 g | Reduce PANSS score, general psychopathologic and total scores |
| [ | 71 first-episode schizophrenia patients aged 16-35 yr, 26 wk | 2.2 g (1.32 g EPA + 0.88 g DHA) | Reduce the intensity of symptoms and improve the level of functioning |
AD, alzheimer's disease; BDI, beck depression inventory; CSF, cerebrospinal fluid; EPDS, edinburgh postnatal depression scale; PANSS, positive and negative syndrome scale.
Altered phospholipids in subjects with Alzheimer's disease (AD)
| Ref. No. | Study design | Sample type | Altered phospholipids |
|---|---|---|---|
| [ | Healthy control (n = 73), amnestic MCI/AD (n = 46), and converter (n = 28) aged 70 yr and older | Plasma | LysoPC a C18:2, PC aa C36:6, PC aa C38:0, PC aa C38:6, PC aa C40:1, PC aa C40:2, PC aa C40:6, and PC ae C40:6 were depleted in the plasma of the converter subjects |
| [ | Healthy control (n = 46), MCI (n = 143), and AD (n = 47) | Serum | PC (18:0/20:4), PC (16:0/18:2), and PC (O-18:0/18:2) were decreased in AD |
| [ | Healthy control (n = 17) and AD (n = 19) | Serum | PC (16:1/16:1), PC (16:1/16:0), PC (16:0/16:0), PC (16:1/18:3), PC (16:0/18:3), PC (16:0/18:2), PC (16:0/18:1), PC (16:0/18:0), PC (18:2/18:2), PC (18:2/18:1), PC (18:1/18:1), and PC (18:0/18:0) were increased in AD, while PC (16:0/20:5), PC (18:2/20:5), PC (16:0/22:6), PC (16:0/22:5), PC (18:1/20:4), PC (18:1/20:3), PC (18:0/20:3), and PC (18:0/22:6) were decreased in AD |
MCI, mild cognitive impairment; PC, phosphatidylcholine; PC aa, diacyl form; PC ae, acyl-alkyl form.